Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Calithera Biosciences stock

Own Calithera Biosciences stock in just a few minutes.

Posted

Fact checked

Calithera Biosciences, Inc is a biotechnology business based in the US. Calithera Biosciences shares (CALA) are listed on the NASDAQ and all prices are listed in US Dollars. Calithera Biosciences employs 90 staff and has a market cap (total outstanding shares value) of USD$289.3 million.

How to buy shares in Calithera Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Calithera Biosciences. Find the stock by name or ticker symbol: CALA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Calithera Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Calithera Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Calithera Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Calithera Biosciences share price

Use our graph to track the performance of CALA stocks over time.

Calithera Biosciences shares at a glance

Information last updated 2020-10-20.
52-week range USD$2.6 - USD$8.04
50-day moving average USD$3.6854
200-day moving average USD$5.0324
Wall St. target price USD$11.1
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.225

Buy Calithera Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Calithera Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Calithera Biosciences financials

Gross profit TTM USD$-76,290,000
Return on assets TTM -33.73%
Return on equity TTM -61.46%
Profit margin 0%
Book value $2.031
Market capitalisation USD$289.3 million

TTM: trailing 12 months

Shorting Calithera Biosciences shares

There are currently 3.2 million Calithera Biosciences shares held short by investors – that's known as Calithera Biosciences's "short interest". This figure is 0.3% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting Calithera Biosciences shares can be evaluated.

Calithera Biosciences's "short interest ratio" (SIR)

Calithera Biosciences's "short interest ratio" (SIR) is the quantity of Calithera Biosciences shares currently shorted divided by the average quantity of Calithera Biosciences shares traded daily (recently around 601927.37430168). Calithera Biosciences's SIR currently stands at 5.37. In other words for every 100,000 Calithera Biosciences shares traded daily on the market, roughly 5370 shares are currently held short.

However Calithera Biosciences's short interest can also be evaluated against the total number of Calithera Biosciences shares, or, against the total number of tradable Calithera Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Calithera Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Calithera Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0821% of the tradable shares (for every 100,000 tradable Calithera Biosciences shares, roughly 82 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Calithera Biosciences.

Find out more about how you can short Calithera Biosciences stock.

Calithera Biosciences share dividends

We're not expecting Calithera Biosciences to pay a dividend over the next 12 months.

Have Calithera Biosciences's shares ever split?

Calithera Biosciences's shares were split on a 1:48 basis on 19 September 2014. So if you had owned 48 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Calithera Biosciences shares – just the quantity. However, indirectly, the new 4700% higher share price could have impacted the market appetite for Calithera Biosciences shares which in turn could have impacted Calithera Biosciences's share price.

Calithera Biosciences share price volatility

Over the last 12 months, Calithera Biosciences's shares have ranged in value from as little as $2.6 up to $8.04. A popular way to gauge a stock's volatility is its "beta".

CALA.US volatility(beta: 1.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calithera Biosciences's is 1.9145. This would suggest that Calithera Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Calithera Biosciences overview

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site